Levosimendán Altan (Levosimendan)

Levosimendan enhances the sensitivity of cardiac troponin C to calcium, which strengthens heart muscle contraction without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation. The combined effect supports the failing heart by increasing output and lowering afterload.

The dosing regimen for levosimendan is individualized and determined by the prescribing clinician based on the patient’s clinical status, weight, and response. Healthcare professionals set the infusion rate and duration according to approved guidelines and local practice.

The safety of levosimendan in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and use is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility by sensitizing troponin C to calcium and adds vasodilatory effects through potassium‑channel activation. This dual mechanism may result in less tachycardia and lower myocardial oxygen consumption compared with agents such as dobutamine or dopamine.

Levosimendán Altan should be stored at 2‑8 °C in a refrigerator, protected from light. The solution must not be frozen or shaken. Keep the product in its original packaging until ready for use to maintain stability.

Levosimendán Altan is given as an intravenous infusion. The initial loading dose is typically administered over 10 minutes, followed by a continuous maintenance infusion. Administration must be performed by qualified healthcare personnel in a setting where cardiac monitoring is available.

Serious risks include severe hypotension, ventricular arrhythmias such as tachycardia, myocardial ischemia, and rare anaphylactic reactions. Continuous blood pressure and ECG monitoring are essential during infusion to detect and manage these events promptly.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug or any of its excipients, those with severe hypotension unresponsive to treatment, and individuals with significant mechanical obstruction of the outflow tract of the heart. Caution is also advised in patients with severe renal or hepatic impairment.